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Frontotemporal dementias (FTD) are the second most common type of presenile dementias, considered to 
be clinically and pathologically different from Alzheimer’s dementia (AD). FTD differs clinically from 
AD because memory loss is rarely an early symptom. Instead, FTD is usually denoted by behavioural 
and language difﬁ culties, and may co-occur with motor neuron disease (MND). Frontotemporal lobar 
degeneration (FTLD) with ubiquitin-positive, tau-negative inclusions (FTLD-U) is the most common 
underlying pathology with and without MND. TAR DNA-binding protein 43 (TDP-43), encoded by the 
TARDBP gene, has been identiﬁ ed as the major pathological protein of FTLD-U with or without MND, 
demonstrating that abnormal TDP-43 alone is sufﬁ cient to cause neurodegeneration. FTLD is a genetically 
complex disorder. A proportion of cases of FTLD-U have various pathogenic mutations in the progranulin 
(GRN) gene. Other FTLD-U entities with TDP-43 proteinopathy include FTLD-U with valosin-containing 
protein (VCP) gene mutation and FTLD with MND linked to chromosome 9p. In contrast, chromosome 
3-linked dementia, a FTLD-U with chromatic modifying protein 2B (CHMP2B) mutation, has TDP-43 
negative inclusions. Thus, TDP-43 deﬁ nes a novel class of neurodegenerative diseases called TDP-43 
proteinopathies. These recent discoveries will contribute to an accurate diagnosis, and facilitate the 
development of diagnosis and therapy.
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Frontotemporal dementias (FTD) are a clinically, 
genetically, and neuropathologically heterogeneous 
group of diseases accounting for up to 20 % of presenile 
dementia cases. FTD is a focal, non-Alzheimer form 
of dementia, clinically characterised as behavioural 
and/or language dysfunction, and may co-occur with 
motor neuron disease (MND) (1). Typically, the 
patient with FTD does not have an amnestic syndrome, 
at least in the early stage of the disease, which 
distinguishes FTD clinically from Alzheimer’s disease 
(AD) (2, 3), but there are exceptions (4). However, 
the clinical diagnosis of FTD may only be considered 
after other potential causes of dementia (e.g. small 
and/or large vessel disease), systemic conditions (e.g., 
hypothyroidism, vitamin B deﬁ ciency), tumours, and 
substance abuse have been excluded. Frontotemporal 
lobar degeneration (FTLD) with ubiquitin-positive, 
tau-negative inclusions (FTLD-U or FTLD-MND-
type) is the most common underlying pathology in 
FTD with and without MND (5). TAR DNA-binding 
protein 43 (TDP-43), a nuclear protein implicated 
in exon skipping and transcription regulation (6, 7, 
8) was recently identiﬁ ed as the major pathological 
protein of sporadic and familial FTLD-U, with and 
without MND, as well as in sporadic amyotrophic 
lateral sclerosis (ALS), (9, 10), and rapidly conﬁ rmed 
by others (11, 12). Pathologic TDP-43 in these 
disorders is abnormally phosphorylated, ubiquitinated 
and cleaved to generate C-terminal fragments, and 
is recovered only from pathologically affected CNS 
regions including hippocampus, neocortex, and 
spinal cord (10). Therefore, the presence of abnormal 
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aggregates of phoshorylated and ubiquitinated 
TDP-43 deﬁ nes a novel class of neurodegenerative 
diseases called TDP-43 proteinopathies that includes 
FTLD-U, FTLD, MND, and ALS. The increasing 
life expectancy will result in increased prevalence of 
neurodegenerative diseases. This review focuses on 
exciting ﬁ ndings providing a number of important 
advances in our understanding of the neuropathology, 
molecular genetics, and biochemistry of FTD, as one 
of neurodegenerative diseases that have occurred 
recently in this rapidly developing ﬁ eld of dementia 
research.
NEUROPATHOLOGY OF FTLD
FTLD comprises a  neuropathological ly 
heterogeneous group of neurodegenerative diseases 
which share the common feature of predominant 
degeneration of the frontal and temporal lobes 
(13-15). FTLD can broadly be divided into two 
main classes, based on abnormal accumulation of 
hyperphosphorylated tau protein: those with tau-
positive and with tau-negative inclusions. Whereas, in 
the past, most attention focused on FTLD associated 
with tau-based pathology and microtubule-associated 
protein tau gene (MAPT) mutations (tauopathies), 
there has recently been greater attention paid to non-
tau or tau-negative FTLD (non-tauopathies) (14). 
FTLD-U accounts for 5 % to 15 % of all dementia 
disorders (16).
GENETIC STUDIES
FTLD is a genetically complex disorder, with 
multiple genetic factors contributing to the disease. A 
positive family history with an autosomal dominant 
pattern of inheritance and high penetrance is usually 
found in one quarter to one half of patients (17, 18). 
Abbreviations:
CBD = corticobasal degeneration
FTDP17= frontotemporal dementia with parkinsonism linked to chromosome 17
PiD = Pick’s disease
PSP = progressive supranuclear palsy
AGD = argyrophilic grain disease
TOD = tangle only dementia
FTLD-MND-type = frontotemporal dementia with motor neuron disease type inclusions
IBMPFD = inclusion body myopathy with Paget’s disease of bone and frontotemporal dementia
DLDH = dementia lacking distinctive histopathology
Figure 1  Spectrum of FTLD (14, 15) in a cohort of 48 cases published elsewhere (2). The FTLD-U (or FTLD-MND-type) is 
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Various pathogenic mutations in the progranulin 
(GRN) gene were recently reported in individuals with 
FTLD-U linked to chromosome 17q21 (19, 20). The 
GRN gene is mutated in 5 % to 10 % of patients with 
FTD and in about 20 % of patients with familial FTD 
(21), similar to that of FTD with MAPT mutations 
(22). For the current list of pathogenic mutations 
in FTLD please refer to: http://www.molgen.ua.ac.
be/FTDMutations/. It is now recognised that FTLD-
U is the most common pathology associated with 
clinical FTLD (5). Also, several genes and a locus on 
chromosome 9 have been linked to familial FTLD-U. 
Genetic defects include mutations in the chromatin 
modifying protein 2B (CHMP2B gene), the cause 
of chromosome 3-linked FTLD, and mutations in 
the valosin-contaning protein (VCP) gene associated 
with inclusion body myopathy, with Paget’s disease, 
and with frontotemporal dementia, which is the 
cause of chromatin 9-linked FTLD (18, 23). Locus 
heterogeneity for FTLD and MND is indicated by the 
presence of other genetic loci at 9p. The ubiquitinated 
pathological protein in FTLD-U has been identiﬁ ed 
as TAR DNA-binding protein 43 (TDP-43) (9-11). As 
more entities are investigated, the pathological TDP-
43 protein is found to be a component of the inclusions 
of an increasing number of neurodegenerative 
diseases.
CLINICAL PHENOTYPE OF FTD
Recently, we retrospectively examined charts 
of 48 FTD individuals in order to find clinical 
differences between FTD and AD. All cases of FTD 
met pathological criteria for FTLD (14, 15). Clinically, 
behavioural and language features, including 
impulsivity, disinhibition, and social withdrawal 
were signiﬁ cantly different between FTD and AD, as 
reported previously (24). The most distinctive feature 
of FTD, on psychometric tests, was a signiﬁ cant 
impairment of frontal lobe functioning, as reported 
earlier (25). The identiﬁ cation of different mutations 
in the GRN gene in hereditary dysphasic disinhibition 
dementia families 1 and 2 (HDDD 1 and HDDD 2) 
(26, 27) links these families to other FTLD-U families 
with GRN mutation (28, 29). A complicating feature 
in both HDDD families is the presence of AD-type 
early memory loss which correlated with coexisting 
AD pathology in almost half of the cases, which 
distinguishes them from other families with no or 
little coexisting neurodegenerative disease (26, 27). 
Interestingly, another family with the same GRN 
A9D mutation has been reported in an individual with 
corticobasal syndrome (30), indicating, again, clinical 
heterogeneity associated with the same mutation.
CONCLUSION
For practicing clinicians, the knowledge that 
changes in behaviour and language difficulties 
distinguish those with FTD from AD is important, 
although clinical and cognitive features may overlap 
between the two. Typically, patients with FTD do not 
have an amnestic syndrome, at least in the early stage 
of the disease, which distinguishes them from AD.
Major discoveries have been made in the recent 
past in the genetics, biochemistry, and neuropathology 
of FTD. TDP-43, encoded by the TARDBP gene, 
is the major pathological protein of FTLD-U with 
or without MND. Thus, TDP-43 defines a novel 
class of neurodegenerative diseases called TDP-43 
proteinopathies. FTLD-U is now recognised as the 
most common pathology associated with clinical 
FTLD. New developments such as the discovery of 
TDP-43 as disease protein have opened new view on 
FTD, as well as its relation to motor neuron disease.
In summary, the new genetic and pathological 
information now opens the way for a novel diagnostic 
approach. The diagnostic responsibility will increase 
with the development of new diagnostic tests. It is 
anticipated that these discoveries will contribute to 
an accurate diagnosis, and facilitate the development 
of speciﬁ c therapy.
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Sažetak
FRONTOTEMPORALNE DEMENCIJE - PRIKAZ NOVIH DOSTIGNUĆA IZ PODRUČJA 
MOLEKULARNE GENETIKE I NEUROPATOLOGIJE
Frontotemporalne demencije (FTD) druga su po učestalosti grupa presenilnih demencija, koja se kliničkim 
simptomima i patologijom razlikuje od Alzheimerove demencije (AD). FTD se razlikuje od AD budući 
da je gubitak memorije rijetko prvi simptom bolesti. Umjesto toga, FTD karakteriziraju smetnje u 
ponašanju i govoru, a mogu se javiti i simptomi bolesti motornog neurona (BMN). Frontotemporalna 
lobarna degeneracija (FTLD) s ubikvitin-pozitivnim, tau-negativnim inkluzijama (FTLD-U) najučestalija 
je patološka slika s BMN-om ili bez njega. Glavni patološki protein FTLD-U s BMN-om ili bez njega je 
protein 43 vezan s DNA (TDP-43), kodiran od gena TARDBP, čija prisutnost je već dovoljna za nastanak 
neurodegenerativnih promjena. Glede genetike, FTLD je kompleksna bolest. Dio bolesnika s patološkom 
slikom FTLD-U pokazuje različite patološke mutacije progranulin (GRN) gena. Ostali FTLD-U entiteti s 
TDP-43-proteinopatijama uključuju: FTLD-U proteinom vezanim s valozinom i FTLD s BMN-om vezanim 
uz kromosom 9p. Nasuprot tomu, demencija vezana na kromosom 3, FTLD-U s CHMP2B-mutacijom, 
sadržava TDP-43-negativne inkluzije. Stoga, TDP-43-protein deﬁ nira novu grupu neurodegenerativnih 
bolesti koje nazivamo TDP-43-proteinopatije. Ova novija otkrića pridonijet će točnijoj dijagnozi i ubrzati 
razvoj dijagnostike i terapije.
KLJUČNE RIJEČI: bolest motornog neurona, frontotemporalna lobarna degeneracija, granulin (GRN) 
mutacije, TARDBP, TDP-43 protein
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